What is Spiriplex?
Spiriplex is a health-focused enterprise dedicated to improving outcomes for individuals affected by allergies and asthma. Leveraging scientific literature and research, the company provides critical information and resources to empower clients in effectively managing their conditions. Spiriplex's core offering centers on delivering reliable insights and solutions for enhanced health management, targeting individuals actively seeking to mitigate the impact of these prevalent health issues.
How much funding has Spiriplex raised?
Spiriplex has raised a total of $99K across 1 funding round:
Debt
$99K
Debt (2021): $99K with participation from PPP
Key Investors in Spiriplex
PPP
Public-Private Partnership
What's next for Spiriplex?
The substantial expansion capital secured by Spiriplex signals a strategic pivot towards scaling its operations and potentially broadening its research initiatives. This investment at a significant Series B/C stage suggests a focus on market penetration, further development of its informational platforms, or the exploration of new therapeutic avenues related to allergy and asthma management. The company is poised to enhance its impact on public health through data-driven solutions and expanded outreach.
See full Spiriplex company page
